Data For New Alzheimer’s Disease Treatment For Agitation To Be Presented at Upcoming ANA Meeting

Data For New Alzheimer’s Disease Treatment For Agitation To Be Presented at Upcoming ANA Meeting
Avanir Pharmaceuticals, Inc. will present their most-recent results from two clinical trials currently underway for treating conditions associated with Alzheimer’s disease (AD). The data is set to be presented at the American Neurological Association’s (ANA) Annual Meeting in Baltimore, Maryland, from October 12-14, 2014. The phase II clinical trial evaluated AVP-923 safety, tolerability, and efficacy for

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *